Analyst Says Alnylam's New Patisiran Data Shows Disease Slowing With Early Intervention, But Survival Benefit Remains Of Interest
Portfolio Pulse from Vandana Singh
Alnylam Pharmaceuticals released new 18-month results from the APOLLO-B Phase 3 study of patisiran, showing sustained favorable effects on functional capacity, health status, and quality of life. The FDA has set an action date of October 8, 2023, and plans to convene a Cardiovascular and Renal Drugs Advisory Committee meeting.
May 22, 2023 | 9:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals' new 18-month results from the APOLLO-B Phase 3 study of patisiran show sustained favorable effects, with an FDA action date set for October 8, 2023.
The new 18-month results from the APOLLO-B Phase 3 study of patisiran show sustained favorable effects on functional capacity, health status, and quality of life. This positive data is likely to have a positive short-term impact on Alnylam Pharmaceuticals' stock price, as it demonstrates the potential effectiveness of the drug. Additionally, the FDA has set an action date of October 8, 2023, which provides a clear timeline for potential regulatory approval, further supporting the positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100